Oct 2026· Cell Reports· Vol 45 10, pp.
118111
· 0 citations· 87 references
Medicine
TL;DR
Large-scale functional screens are developed and performed to identify non-coding regulatory elements whose mutations drive cancer development in non-transformed human breast epithelial cells and mouse models of breast and skin cancer.
Abstract
Whole-genome sequencing has revealed hundreds of cancer driver mutations in protein-coding genes, while our knowledge of how non-coding mutations contribute to tumorigenesis remains limited. Here, we develop and perform large-scale functional screens to identify non-coding regulatory elements whose mutations drive cancer development in non-transformed human breast epithelial cells and mouse models of breast and skin cancer. We identify 12 frequently mutated regulatory elements associated with 16 genes as candidate cancer drivers. Mechanistically, we characterize two elements associated with the microRNA MIR21 and the tumor suppressor gene, ZFP36L2. Mutating these regulatory elements dysregulates the expression of MIR21 and ZFP36L2, thereby leading to oncogenic transformation. We identify ZFP36L2 as a p53 target gene and find that mutating the p53-binding motif in the ZFP36L2 promoter is sufficient to drive tumorigenesis. Conceptually, our data indicate that cancer driver mutations in non-coding regulatory elements are much more prevalent and potent than initially assumed.
High-coverage whole-genome sequencing, large-scale transcriptomics, and eQTL are used to map male cancer cell lines, revealing a region-specific LOY landscape with recurrent euchromatic deletions affecting protein-coding genes and non-coding elements and motivating validation in primary tumor cohorts.
Trini Nguyen, Aditi Kuchi, Hong-Yu Liu et al.· Communications Biology· 0 citations
The inactivation of tumour suppressor genes is a key step in cancer development, and is usually achieved by homozygous loss. In prostate cancer, however, large genomic regions are often hemizygously lost, which complicates the identification of putative tumour suppressors in these regions. Here, we develop Epi2Hit, an...
Daria Kiriy, F. Favero, C. Gerhäuser et al.· Nature Communications· 1 citation
Large-scale genome sequencing analyses have identified driver gene mutations (DGMs) in most cancers as well as their associated tumorigenic mechanisms. However, a small fraction of cancers are not positive for these canonical DGMs, leaving the mechanisms underpinning their formation a mystery. We hypothesized that cano...
Prostate cancer is a common malignancy with a heterogeneous disease course. Prior studies have identified a paucity of point mutations in protein-coding genes and only a few clinically relevant driver alterations. Here, using the Pan Prostate Cancer Group whole genome sequencing dataset from 1001 men, we perform an int...
D. Pellegrina, Daria Kiriy, Kevin C. L. Cheng et al.· Nature Communications· 1 citation
Although tumor protein p53 (TP53) mutations are among the most common lesions in epithelial cancers, how p53 loss drives unrestrained clonal expansion remains unclear. Working with mouse epidermis, we found that p53 suppresses clonal expansion by limiting progenitor self-renewal. Integrating chromatin immunoprecipitati...
Qi-Wen Gan, Wei Li, Rachel K. Lex et al.· Science· 1 citation
Background/Objectives: Colorectal cancer (CRC) is among the most diagnosed malignancies and is a leading cause of cancer-related deaths globally. Beyond canonical CRC driver mutations, additional molecular alterations such as dysregulated gene expression and epigenetic reprogramming shape the disease behavior and may r...
Abdullah A. Alqasem, Waad Al-Burayk, Muneira Habjar et al.· Genes· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.